Cargando…
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib. Lovastatin and other inhibitors of HMG-CoA reductase demonstrated to exhibit antineoplasmatic and proapoptotic properties in numerous in vitro studies involving myeloma cel...
Autores principales: | Hus, Marek, Grzasko, Norbert, Szostek, Marta, Pluta, Andrzej, Helbig, Grzegorz, Woszczyk, Dariusz, Adamczyk-Cioch, Maria, Jawniak, Dariusz, Legiec, Wojciech, Morawska, Marta, Kozinska, Justyna, Waciński, Piotr, Dmoszynska, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168480/ https://www.ncbi.nlm.nih.gov/pubmed/21698395 http://dx.doi.org/10.1007/s00277-011-1276-2 |
Ejemplares similares
-
An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
por: Hus, I, et al.
Publicado: (2004) -
Systemic Immunomodulatory Effects of Combinatorial Treatment of Thalidomide and Dexamethasone on T Cells and Other Immune Cells
por: Kim, Eun Jee, et al.
Publicado: (2021) -
New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014) -
Immunomodulatory effects of thalidomide in an experimental brain death liver donor model
por: Santana, Alexandre Chagas, et al.
Publicado: (2021) -
High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
por: Hus, Iwona, et al.
Publicado: (2019)